BENZENO SHARON 4
4 · Adaptive Biotechnologies Corp · Filed Dec 8, 2025
Insider Transaction Report
Form 4
BENZENO SHARON
Chief Commercial Ofc Imm Med
Transactions
- Exercise/Conversion
Common Stock
2025-12-04$12.14/sh+4,290$52,081→ 301,081 total - Exercise/Conversion
Common Stock
2025-12-04$8.46/sh+4,157$35,168→ 305,238 total - Sale
Common Stock
2025-12-04$16.85/sh−12,604$212,377→ 296,791 total - Exercise/Conversion
Stock Option (right to buy)
2025-12-04−4,290→ 12,871 totalExercise: $12.14Exp: 2032-03-04→ Common Stock (4,290 underlying) - Exercise/Conversion
Stock Option (right to buy)
2025-12-04−4,157→ 62,360 totalExercise: $8.46Exp: 2033-03-06→ Common Stock (4,157 underlying)
Footnotes (5)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.
- [F2]The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.66 to $16.93, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- [F3]The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
- [F4]The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
- [F5]The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.